Delta Global Management LP Makes New Investment in Zimmer Biomet Holdings, Inc. $ZBH

Delta Global Management LP acquired a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 22,154 shares of the medical equipment provider’s stock, valued at approximately $2,182,000.

Other large investors have also made changes to their positions in the company. Key Financial Inc raised its stake in Zimmer Biomet by 164.6% in the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 163 shares during the last quarter. Cullen Frost Bankers Inc. boosted its stake in shares of Zimmer Biomet by 66.7% during the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 116 shares during the last quarter. Cary Street Partners Investment Advisory LLC grew its holdings in shares of Zimmer Biomet by 83.7% during the second quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 149 shares in the last quarter. Root Financial Partners LLC acquired a new position in shares of Zimmer Biomet in the third quarter valued at approximately $31,000. Finally, Mather Group LLC. acquired a new position in shares of Zimmer Biomet in the third quarter valued at approximately $36,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insider Buying and Selling

In other news, SVP Lori Winkler sold 2,650 shares of the firm’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the transaction, the senior vice president directly owned 10,224 shares in the company, valued at $967,803.84. This trade represents a 20.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.70% of the stock is owned by corporate insiders.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $93.36 on Tuesday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98. The firm has a market capitalization of $18.27 billion, a price-to-earnings ratio of 26.37, a price-to-earnings-growth ratio of 1.90 and a beta of 0.58. Zimmer Biomet Holdings, Inc. has a one year low of $84.59 and a one year high of $114.44. The company has a 50 day moving average price of $92.42 and a 200 day moving average price of $95.03.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.38 by $0.04. The company had revenue of $2.24 billion during the quarter, compared to analysts’ expectations of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The business’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same period in the previous year, the company earned $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s payout ratio is 27.12%.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. BTIG Research restated a “buy” rating and set a $112.00 target price on shares of Zimmer Biomet in a research report on Tuesday, February 10th. William Blair started coverage on Zimmer Biomet in a report on Friday, February 20th. They issued a “market perform” rating for the company. Evercore upgraded Zimmer Biomet from an “in-line” rating to an “outperform” rating and raised their price objective for the stock from $94.00 to $120.00 in a report on Monday, January 5th. Wells Fargo & Company lifted their price objective on Zimmer Biomet from $93.00 to $98.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 11th. Finally, Robert W. Baird reiterated a “neutral” rating and issued a $100.00 target price (down from $117.00) on shares of Zimmer Biomet in a research note on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and an average price target of $106.20.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.